Bevacizumab (anti-VEGF)

What it is

Bevacizumab is a drug that targets the growth of tumor blood vessels by blocking a signal called VEGF (vascular endothelial growth factor). In gliomas, it is used mainly for recurrent glioblastoma, where it can reduce swelling and improve symptoms, though it does not typically cure the tumor.

Understanding Bevacizumab (anti-VEGF)

Aggressive gliomas stimulate abnormal blood vessel growth (angiogenesis) to fuel their growth, and bevacizumab blocks the VEGF signal that drives this. Its effects in glioblastoma are notable for reducing the leakiness of tumor vessels, which decreases swelling (edema) and the associated symptoms and pressure — often providing symptomatic benefit and allowing reduction of steroids. It is given intravenously. Bevacizumab is used particularly at recurrence of glioblastoma. Importantly, while it can improve symptoms and imaging appearance (reducing enhancement), this improvement can partly reflect its effect on blood vessels rather than true tumor shrinkage (see pseudoresponse), and it has not been shown to extend overall survival in the way that would make it curative — so its role is largely about symptom control and quality of life. It has specific side effects that are monitored. Understanding bevacizumab in gliomas clarifies a blood-vessel-targeting drug used mainly for symptom control in recurrent glioblastoma.

Why it matters

Understanding bevacizumab helps patients and families see a drug used mainly for recurrent glioblastoma — reducing swelling and improving symptoms — while recognizing its role is largely symptom control and quality of life rather than cure.